Risk of Thromboembolism in Heart Failure | Zendy

Ronald S. Freudenberger | Zendy; Anne S. Hellkamp | Zendy; Jonathan L. Halperin | Zendy; Jeanne E. Poole | Zendy; Jill Anderson | Zendy; George Johnson | Zendy; Daniel B. Mark | Zendy; Kerry L. Lee | Zendy; Gust H. Bardy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk of Thromboembolism in Heart Failure

Author(s) -

Ronald S. Freudenberger,

Anne S. Hellkamp,

Jonathan L. Halperin,

Jeanne E. Poole,

Jill Anderson,

George Johnson,

Daniel B. Mark,

Kerry L. Lee,

Gust H. Bardy

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.661397

Subject(s) - medicine , amiodarone , atrial fibrillation , ejection fraction , heart failure , cardiology , hazard ratio , stroke (engine) , placebo , randomized controlled trial , incidence (geometry) , pulmonary embolism , confidence interval , mechanical engineering , physics , alternative medicine , optics , pathology , engineering

In patients with heart failure, rates of clinically apparent stroke range from 1.3% to 3.5% per year. Little is known about the incidence and risk factors in the absence of atrial fibrillation. In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research